Hadean Ventures
VC Fund
Oslo, Norway
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
- Total investments:
- 33
- Last investment:
- Lead investor:
- 45%
- Fund size:
- $105M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Hadean Ventures invests in
Stages Hadean Ventures invests in
Countries Hadean Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.3M–$79M
- Series B
- $4.5M–$75M
Investment Focus
Industry
- Biotechnology 17 (52%)
- Health Care 13 (39%)
- Medical 6 (18%)
- Pharmaceutical 5 (15%)
- Therapeutics 3 (9%)
Stage
- Series A 10 (30%)
- Series B 5 (15%)
- Series C 3 (9%)
- Funding Round 3 (9%)
- Venture - Series Unknown 3 (9%)
Country
- Sweden 5 (15%)
- Norway 4 (12%)
- Austria 3 (9%)
- Germany 3 (9%)
- Spain 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Florian Eckhardt
Senior Investment Director
|
Senior Investment Director | Total investments: 0 | Find email | |
Ingrid Akay
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 7 | Find email | |
Ingrid Beyer
Head of Investor Relations
|
Head of Investor Relations | Total investments: 0 | Find email | |
Roger Franklin
Partner
|
Partner | Total investments: 6 | Find email | |
Walter Stockinger
Managing Partner
|
Managing Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TargED Biopharmaceuticals
|
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M / Series A / Dec 16, 2025 | |
Step Pharma
|
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M / Series C / Oct 15, 2025 | |
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | |
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $4.5M / Series B / Jul 22, 2025 | |
Actithera
|
Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M / Series A / Jul 09, 2025 | |
|
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $27.6M / Series B / Jan 20, 2025 | |
SciRhom
|
SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development. | $68.1M / Series A / Jul 09, 2024 | |
|
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $46.5M / Series B / May 03, 2023 | |
Complement Therapeutics
|
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies. | $78.7M / Series A / Apr 17, 2023 | |
Alex Therapeutics
|
Alex Therapeutics, a digital therapeutics company, is changing the way clinicians provide support for patients to change unwanted habits leading to poor medical outcomes. Our proprietary AI-platform is used as the basis when we develop CE-marked software medical devices (Class I) apps for a variety of therapeutic areas. | $5.1M / Venture - Series Unknown / Mar 03, 2023 | |
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Hadean Ventures invest in?
Hadean Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 33 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hadean Ventures's check size?
Hadean Ventures typically joins rounds of $4.3M–$79M at Series A and $4.5M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hadean Ventures participates in.
How do I contact Hadean Ventures?
Public channels for Hadean Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hadean Ventures?
The team at Hadean Ventures includes Florian Eckhardt (Senior Investment Director), Ingrid Akay (Founder and Managing Partner) and Ingrid Beyer (Head of Investor Relations). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
